Abstract C63: Biological characterization of GSK2126458, a novel and potent inhibitor of phosphoinositide 3-kinase and the mammalian target of rapamycin (mTOR)
Mary Ann Hardwicke(GlaxoSmithKline (United States)), Kurt R. Auger(Research Triangle Park Foundation), Jeffrey D. Carson(GlaxoSmithKline (United States)), Richard R. Gontarek(South College), Hong Lu(Shandong Freshwater Fisheries Research Institute), Ramona Plant(Enzo Life Sciences (United States)), Catherine A. Oleykowski(Molecular Oncology (United States)), Richard Wooster(GlaxoSmithKline (United States)), Dashyant Dhanak(Wilmington University), Christine Gardiner(South College), Steven D. Knight(GlaxoSmithKline (United States)), S. Gilbert, Peter J. Tummino(Intarcia Therapeutics (United States)), Jeffrey R. Jackson(New Frontier), Chiu-Mei Sung(South College), Melody Diamond(South College), Glenn Van Aller(GlaxoSmithKline (United States)), Jamin Wang(GlaxoSmithKline (United States)), Lusong Luo(BeiGene (China)), David S. Sutton(GlaxoSmithKline (United States))
Cited by 1
Related Papers
Genome sequencing in microfabricated high-density picolitre reactors
|Nature|2005|7.7k
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
|Nature|2011|1.5k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k